← All Sponsors
SPONSOR

Anthos Therapeutics, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Atrial Fibrillation (AF)
NCT05712200 Phase 3
Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Atrial Fibrillation (AF)
United States, Argentina, Brazil View Trial →